Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
16. |
ECCT/21/07/04 | Healthy Route A Non-Interventional Pilot Study to Evaluate A Machine-Learning Algorithm for Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate from Digital Retinal Images |
Principal Investigator(s) 1. Mansoor Noorali Saleh 2. Videlis Nduba Site(s) in Kenya 1. Aga Khan University Hospital Clinical Research Unit (Nairobi City county) 2. Kenya Medical Research Institute CRDR (Nairobi City county) |
View |
17. |
21/06/16 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older |
Principal Investigator(s) 1. Fredrick Sawe Site(s) in Kenya 1. Kenya Medical Research Institute, Kisumu Clinical Reseach Site (Kisumu county) 2. KEMRI/Walter Reed Project - Clinical Research Center, Kericho (Kericho county) 3. Ganjoni Clinic - University of Washington/University of Nairobi, Mombasa (Mombasa county) 4. Partners in Health Research and Development, Thika (Kiambu county) 5. KARGENO RESEARCH AND POLICY HUB (Kisumu county) 6. The Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI) (Nairobi City county) 7. KEMRI-USAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 8. Moi University Clinical Research Centre (MUCRC), Chandaria Cancer and Chronic Diseases Center (CCCDC) (Uasin Gishu county) 9. Aga Khan University Hospital (Nairobi City county) 10. KEMRI CCR-Butere County Hospital Site (Kakamega county) |
View |
18. |
ECCT/21/06/03 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older |
Principal Investigator(s) 1. PROF.ELIZABETH ANNE BUKUSI 2. MARICIANAH A ONONO Site(s) in Kenya 1. Kenya Medical Research Institute (KEMRI) Center for Microbiology Research - Research Care and Training Program (KEMRI CMRRCTP) (Kisumu county) 2. KEMRI CCRButere County Hospital Site (Kakamega county) 3. Aga Khan University Hospital (Nairobi City county) 4. Kenya Medical Research Institute CGHR (Kisumu county) 5. Kenya Medical Research Institute (Nairobi City county) 6. KEMRI/CCR Partners in Health R&D (PHRD (Kiambu county) 7. KAVI-Institute of Clinical Research, University of Nairobi (Nairobi City county) 8. Ganjoni Clinic (Mombasa county) 9. KEMRI-UAMRD-A/K, Kombewa Clinical Research Cente (Kisumu county) 10. KEMRI/Walter Reed Project Research Center (Kericho county) |
View |
19. |
ECCT/21/06/12 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI/Walter Reed Project Research Center (Kericho county) 3. Kenya Medical Research Institute (Kisumu county) 4. Ganjoni Clinic (Mombasa county) 5. KEMRI/CCR Partners in Health R&D (PHRD) (Nairobi City county) 6. Kenya Medical Research Institute (Nairobi City county) 7. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 8. Aga Khan University Hospital (Nairobi City county) 9. KEMRI CCR-Butere County Hospital Site (Bung\'oma county) |
View |
20. |
ECCT/17/08/03 | Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria. |
Principal Investigator(s) 1. Grace Kiringa Kaguthi Site(s) in Kenya KEMRI Siaya |
View |